… particularly wary of the 2026 patent expiry of semaglutide, after … and improved care solutions. Patent expiry is a natural phase … expected to go off-patent by the end of … -Shaw, Executive Chairperson of Biocon Limited. Biocon, which already markets liraglutide …

… jurisdiction, preliminary injunctions, and patent validity. Background Regeneron holds … of detailed patent specifications and robust patent rights in biopharmaceutical patent litigation. … Inc., Amgen USA, Inc., Biocon Biologics Inc., Celltrion, Inc., …

… release versions, seek additional patent protections to extend commercial viability … Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is … Viking Therapeutics Lexicon Pharmaceuticals Biocon AstraZeneca Key Attributes: Report …

… Term Upside Biocon is closely watching when blockbuster drug patents expire. Semaglutide … Strong Performance Across Business Segments Biocon’s core segments demonstrated solid … evaluating a merger between Biocon Biologics and Biocon Ltd, scrapping earlier …

… and Managing Director, Biocon Ltd Pharma major Biocon says its businesses … are expected to go off-patent in the US and Europe … window for biosimilar players like Biocon, Mittal explained. In the … of a merger between Biocon Biologics and Biocon Ltd, a move that …

… diabetes unless non-patented drugmakers such as Biocon Ltd. step in … biosimilar insulin-pen producers like Biocon, according to the foundation … major drugmakers along with Biocon on their focus over … Martinez said. Bengaluru-based Biocon is doubling down on its …

… Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in … Mittal told Mint. Overall, Biocon reported consolidated revenue of ₹ … financial commitments related to Biocon and its subsidiaries,” Mittal … and Wegovy, goes off-patent in countries like India, …

… Ustekinumab2 In a separate development, Biocon Biologics announced significant market access … Over Aflibercept Biosimilar3 In more Biocon news, Biocon Biologics has reached a … an appeal concerning US patent US11084865, allowing Biocon to launch Yesafili in …

On April 15, 2025, Biocon announced it reached a settlement … Court also found Mylan and Biocon had not proven the claims … biosimilar of EYLEA® to launch. Biocon is the first to settle … filed IPRs against the ’865 patent that are awaiting institution decisions …

… in In re: Aflibercept Patent Litigation (MDL No.: 1 … Mylan Pharmaceuticals, Inc. and Biocon Biologics, Inc. (“the Parties … against Amgen, Mylan/Biocon, Celltrion, Formycon, Samsung, … According to Biocon, the settlement agreement enables Biocon to launch …